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Abstract
Background Narcolepsy is a chronic primary sleep disorder,
characterized by excessive daytime sleepiness and sleep dys-
function with or without cataplexy. Narcolepsy is uncommon,
with a low prevalence rate which makes it difficult to diagnose
definitively without a complex series of tests and a detailed
history. The aim of this study was to review patients referred
to a tertiary sleep centre who had been labelled with a diag-
nosis of narcolepsy prior to referral in order to assess if the
diagnosis was accurate, and if not, to determine the cause of
diagnostic misattribution.
Methods All patients seen at a sleep centre from 2007–2013
(n = 551) who underwent detailed objective testing including
an MSLT PSG, as well as wearing an actigraphy watch and
completing a sleep diary for 2 weeks, were assessed for a pre-
referral and final diagnosis of narcolepsy.
Results Of the 41 directly referred patients with a diagnostic
label of narcolepsy, 19 (46%)were subsequently confirmed to
have narcolepsy on objective testing and assessment by a
sleep physician using ICSD-2 criteria.
Conclusions The diagnosis of narcolepsy was incorrectly
attributed to almost 50 % of patients labelled with a diag-
nosis of narcolepsy who were referred for further opinion
by a variety of specialists and generalists. Accurate diag-
nosis of narcolepsy is critical for many reasons, such as
the impact it has on quality of life, driving, employment,
insurance and pregnancy in women as well as medication
management.
Keywords Narcolepsy . Diagnosis .Misdiagnosis .
Cataplexy .MSLT
Introduction
Narcolepsy is a chronic primary sleep disorder, characterized
by excessive daytime sleepiness (EDS) with symptoms of
rapid eye movement (REM) and sleep dysfunction (i.e. sleep
paralysis, hypnagogic hallucinations), with or without cata-
plexy (muscle weakness). Narcolepsy is uncommon and the
estimated prevalence ranges from 0.01 to 0.05 % worldwide.
[1] The low prevalence means a definitive diagnosis of narco-
lepsy can be complex and should incorporate a detailed pre-
senting history, assessment of sleep-wake cycles, assessment
of sleep deprivation, subjective testing (sleep diary) and ob-
jective testing (polysomnography (PSG), actigraphy, multiple
sleep latency testing (MSLT) including drug-testing of urine,
human leukocyte antigen (HLA) typing and lumbar puncture
to measure CSF hypocretin-1 (orexin) levels) [2].
Even with the use of the International Classification of
Sleep Disorders-2 (ICSD-2) [9] and the International
Classification of Sleep Disorders-3 (ICSD-3) [10] (since
2014), uncertainty with diagnosis may persist with the most
experienced clinicians, given that the symptoms of narcolepsy
can often be mimicked by other sleep disorders (e.g. sleep
disordered breathing) [11] or overlap with psychiatric
symptomology. [8] Patients have beenmisdiagnosed with nar-
colepsy on the basis of clinical judgement alone, resulting in
inappropriate treatment. [3, 4] The aim of this study was to
review patients who had been labelled with a diagnosis of
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narcolepsy by a variety of specialists and generalists prior to
referral to a tertiary sleep centre for a second opinion and/or
continued management, as well as to determine the basis for
any diagnostic misattribution.
Methods
A database comprising all patients seen at a tertiary referral
sleep centre undergoing MSLT between October 2007 and
July 2013 (n = 551) was cross-examined. ‘Diagnosis of nar-
colepsy’ on the referral letter was defined as patients given a
diagnosis of ‘narcolepsy’, patients labelledwith ‘probable nar-
colepsy’ (with/without treatment) and patients deemed as
‘possibly’ having narcolepsy provided they had received treat-
ment with stimulant medication prior to referral. All patient
referrals came from regional centres that did not have exper-
tise in non-respiratory sleep medicine. Most patients had re-
ceived little to no assessment or testing for narcolepsy before
presenting at the sleep clinic (very few had a limited study or
PSG, but none had an MSLT). The ICSD-2 [9] was used to
determine criteria for the narcolepsy and cataplexy diagnosis.
All patients were subsequently reviewed by one of two sleep
specialists in the clinic. Given the frequency of comorbidity of
other sleep disorders in the narcolepsy population (e.g. ob-
structive sleep apnoea), all patients underwent an MSLT and
PSG and wore an actigraphy watch and kept a sleep diary for
2 weeks prior to in-lab testing. All patients underwent further
assessment in the sleep clinic to ensure that symptoms were
more likely as a result of narcolepsy and not due to other sleep
disorders.
Sole reliance for diagnosis was not placed on the MSLT.
TheMSLTshould not be used as a diagnostic tool in isolation,
[15] due to its limited test-retest reliability, sometimes yielding
misleading or false positive or negative results, [12] and its
inadequate exclusion of other sleep disorders (e.g. OSAHS).
[3] Arand et al. [15] recommend improving the reliability of
the MSLT by combining it with the results from a PSG and
obtaining a suitable history of the patient. The sleep specialists
reviewed the referrals in addition to obtaining detailed history
directly from the patient and acquiring information from ob-
jective test results from actigraphy over 2 weeks, PSG follow-
ed by MSLT, a urine drug screen, as well as a subjective 2-
week sleep diary. Difficult cases were discussed at multi-
disciplinary meetings and diagnosis was achieved by consen-
sus and further review. Investigation and scoring of sleep data
were conducted in a blinded manner; technicians who scored
the data were not involved with history taking nor allowed to
review the patient files to prevent any bias in scoring. Specific
ethical approval was not considered necessary, as the Ethics
Advisory Committee in Edinburgh does not require approval
for case series.
Data were gathered on presenting history, medication, re-
ferral/diagnosis, objective investigations, co-morbidities and
anthropometrics. Analysis, using standard statistical tech-
niques, was undertaken with SPSS (IBM, v.19). Significance
was taken at p ≤ 0.05, and all tests were two-tailed.
Results
Of the 41 patients referred with a ‘diagnosis of narcolepsy’
over the 6-year period, only 19 (46%) were confirmed to have
narcolepsy after further assessment and objective testing. The
source of the initial diagnosis in the majority (n = 18) was a
general practitioner; in the remainder, diagnoses had been
made by a neurologist (n = 8), a regional sleep clinic
(n = 9), or respiratory physician (n = 6).
Females were significantly more likely to be diagnosed
with narcolepsy than males (15 vs. 7; p = 0.002).
A history of cataplexy was present in 84 % of the con-
firmed narcoleptic patients and 27 % of the pre-reported
non-narcoleptics (p < 0.001). EDS was measured subjectively
by the Epworth sleepiness scale, [5] and the results were
equivalent between groups (15.15 ± 5.43 in narcoleptics vs.
15.50 ± 4.53 in non-narcoleptics, p = 0.85).
The median sleep onset latency on overnight PSG was
lower in patients with confirmed narcolepsy than for patients
without confirmed narcolepsy (6.5 ± 7.86, p = 0.005 vs.
21.5 ± 34.63, p < 0.0001), as was mean sleep latency on
MSLT (3.65 ± 2.95 vs. 10.20 ± 4.86, p < 0.0001). All con-
firmed narcoleptics experienced at least two SOREMPs on the
MSLT. Six non-narcoleptics were able to achieve REM sleep
on the MLST. Mean REM latency was significantly lower in
the confirmed narcoleptics vs. non-narcoleptics (2.7 vs.
7.8 min, p = 0.007). The number of sleep onset REM-
periods was greater in patients with confirmed narcolepsy
compared to those without (3.1 ± 1.1 vs 1.6 ± 0.8,
p = 0.004). DQB1*0602 alleles were found in 90 % of the
confirmed narcolepsy patients, in 40 % of the non-narcoleptic
patients (p = 0.037) and in the three (16 %) patients who had
narcolepsywithout cataplexy. Despite the fact that 90–95% of
the narcolepsy population will have a positive HLA for nar-
colepsy, [13] we used the HLA markers as an additive factor,
not the only component, to support the diagnosis of narcolep-
sy. Three non-narcoleptic patients who had CSF-hypocretin-1
measured had entirely normal levels (>110 pg/ml).
Only three patients without narcolepsy had no discern-
ible explanation for their symptoms. Diagnoses in the
remaining 19 were obstructive sleep apnoea syndrome
(n = 10), depression/anxiety (n = 3), sleep deprivation
(n = 3), irregular sleep/wake cycles (n = 2) and
parasomnia (n = 1) (Table 1). Thus, non-narcoleptics
and patients with EDS differed from true narcoleptics
determined by the assessment tests described above.
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Table 1 Demographic and diagnosis information at referral for 41 patients referred with a ‘diagnosis of narcolepsy’
Case Age Prior
diagnosis
Medication PSG results MSLT results Drug
screena
HLA type Features
of
cataplexy
Final
diagnosis
1 28 Probable
Nx
None SE: 87.6 %
SOLmin: 3.4
REML: 0 min
AHI: 52.9
events/h
MSL: 2.0 min
MREML: 0.3
No. naps with
REM: 4
Negative Blood could
not be
obtained or
patient
refused
Present True Nx
2 26 Probable
Nx
None SE: 84.6 %
SOLmin: 2.5
REML: 0.5 min
AHI: 10.1
events/h
MSL: 1.9 min
MREML: 2.6
No. naps with
REM: 4
Negative DQB1*06:02 Present True Nx
3 56 Nx Dipyridamole, ezetimibe,
aspirin, perindopril
erbumine, bendroflumet-
hiazide, co-codamol
SE: 67.3 %
SOLmin: 26.0
REML: 52.0 min
AHI: 34.6
events/h
MSL: 8.2 min
MREML:
11.0
No. naps with
REM: 1
Negative Negative Absent OSAHS
4 55 Nx Aspirin, bisoprolol, clenil
modulite, co-dydramol,
furosemide, nitroglycerin,
nicorandil, ramipril,
salbutamol, simvastatin
SE: 51.5 %
SOLmin: 161.0
REML: 95.0 min
AHI: 17.8
events/h
MSL:
18.0 min
MREML: 0
No. naps with
REM: 0
Negative Negative Absent Depression/
anxiety
5 65 Probable
Nx
None SE: 73.4 %
SOLmin: 38.0
REML:
45.5 min AHI:
13.6 events/h
MSL:
15.5 min
MREML:
0 No. naps
with REM:
0
Negative Negative Absent OSAHS
6 37 Nx None SE: 88.2 %
SOLmin: 9.0
REML: 59.0 min
AHI: 8.7 events/h
MSL:
11.6 min
MREML: 0
No. naps with
REM: 0
Urine could
not be
obtained
or patient
refused
DQB1*0603/
08/14,
HLA-
DQ-
A1*0103
Present Depression/
anxiety
7 31 Nx None SE: 85.1 %
SOLmin: 6.0
REML: 1.0 min
AHI: 10.7
events/h
MSL: 4.4 min
MREML: 1.0
No. naps with
REM: 3
Negative DQB1*06:02 Absent True Nx
8 31 Probable
Nx
Lansoprazole, thyroxine SE: 83.0 %
SOLmin: 26.5
REML:
95.5 min AHI:
23.4 events/h
MSL: 3.9 min
MREML:
13.3
No. naps with
REM: 2
Negative DQB1*0602 Present Sleep
deprivation
9 23 Probable
Nx
Salbutamol, oral contraceptive,
betamethasone cream,
beclomethasonedipropionate
inhaler,
SE: 93.0 %
SOLmin: 6.0
REML: 57.0 min
AHI: 8.2 events/h
MSL:
11.3 min
MREML: 0
No. naps with
REM: 0
Negative Blood could
not be
obtained or
patient
refused
Absent True Nx
10 65 Nx Nitroglycerin, co-codamol,
frusemide, telmisartan,
rosuvastatin, cordarone,
warfarin
SE: 52.1 %
SOLmin: 1.5
REML:
223.5 min
AHI: 25.6
events/h
MSL: 8.0 min
MREML: 0
No. naps with
REM: 0
Negative Positive but
type not
recorded
Absent OSAHS
11 50 Probable
Nx
Clonidine SE: 68.2 %
SOLmin: 70.0
REML:
322.0 min
AHI: 10.3
events/h
MSL:
14.0 min
MREML: 0
No. naps with
REM: 0
Positive Blood could
not be
obtained or
patient
refused
Present Irregular
sleep
12 51 Nx None SE: 85.3 %
SOLmin: 6.5
MSL: 1.8 min
MREML: 6.3
Negative Present True Nx
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Table 1 (continued)
Case Age Prior
diagnosis
Medication PSG results MSLT results Drug
screena
HLA type Features
of
cataplexy
Final
diagnosis
REML: 75.0 min
AHI: 10.9 events/
h
No. naps with
REM: 3
DQB1*06,
DRB1*15,
DQA1*01
13 30 Probable
Nx
None SE: 81.3 %
SOLmin: 16.5
REML:
134.0 min
AHI: 19.2
events/h
MSL: 3.4 min
MREML: 3.4
No. naps with
REM: 4
Negative DQB1*06,
DRB1*15,
DQA1*01
Present True Nx
14 29 Nx Pemoline, clomipramine,
fluoxetine, cetirizine,
selegiline, homeopathic
opium, oral contraceptive
SE: 91.5 %
SOLmin: 2.5
REML: 61.5 min
AHI: 1.0 events/h
MSL: 0.8 min
MREML: 0.3
No. naps with
REM: 4
Negative Blood could
not be
obtained or
patient
refused
Present True Nx
15 48 Probable
Nx
Thyroxine, cetirizine SE: 73.6 %
SOLmin: 7.5
REML: 0 min
AHI: 34.3
events/h
MSL: 2.1 min
MREML: 1.0
No. naps with
REM: 4
Negative Blood could
not be
obtained or
patient
refused
Present True Nx
16 30 Probable
Nx
Oral contraceptive SE: 88.4 %
SOLmin: 30.0
REML: 76.5 min
AHI: 4.3 events/h
MSL: 7.5 min
MREML: 3.0
No. naps with
REM: 1
Urine could
not be
obtained
or patient
refused
Blood could
not be
obtained or
patient
refused
Present True Nx
17 34 Nx None SE: 0
SOLmin: 0
REML: 0 min
AHI: 0 events/h
MSL: 6.5 min
MREML:
15.3
No. naps with
REM: 2
Negative Blood could
not be
obtained or
patient
refused
Present True Nx
18 44 Nx Dipyridamole, esomeprazole,
aspirin, simvastatin, quinine
SE: 78.6 %
SOLmin: 14.0
REML:
115.0 min
AHI: 35.3
events/h
MSL:
17.3 min
MREML: 0
No. naps with
REM: 0
Negative Negative Absent OSAHS
19 33 Nx Orlistat SE: 86.4 %
SOLmin: 1.0
REML: 2.5 min
AHI: 8.8 events/h
MSL: 0.8 min
MREML: 1.0
No. naps with
REM: 4
Negative DQB1*0602 Present True Nx
20 30 Nx Melatonin SE: 71.6 %
SOLmin: 27.0
REML: 61.0 min
AHI: 10.3
events/h
MSL: 3.8 min
MREML: 2.7
No. naps with
REM: 3
Negative DQB1*0602 Absent Poor sleep
hygiene
21 32 Probable
Nx
Pramipexole, pregabalin SE: 81.8 %
SOLmin: 21.0
REML:
104.0 min
AHI: 9.5 events/h
MSL: 6.1 min
MREML:
10.5
No. naps with
REM: 1
Positive Negative Present Parasomnia
22 28 Nx None SE: 78.5 %
SOLmin: 51.0
REML: 32.5 min
AHI: 18.7
events/h
MSL:
13.6 min
MREML: 0
No. naps with
REM: 0
Negative Blood could
not be
obtained or
patient
refused
Absent OSAHS
23 69 Nx Zopiclone, trazadone,
thyroxine, tramadol,
omeprazole
SE: 68.5 %
SOLmin: 23.0
REML: 68.0 min
AHI: 19.2
events/h
MSL: 1.1 min
MREML: 2.5
No. naps with
REM: 2
Negative Positive but
type not
recorded
Present True Nx
24 42 Nx None SE: 55.5 % MSL: 4.1 min Positive Present
Sleep Breath
Table 1 (continued)
Case Age Prior
diagnosis
Medication PSG results MSLT results Drug
screena
HLA type Features
of
cataplexy
Final
diagnosis
SOLmin: 7.5
REML: 89.0 min
AHI: 30.5
events/h
MREML: 1.3
No. naps with
REM: 2
DQB1*0602/
14/15/16/
19/20/23/
24/33
Depression/
anxiety
25 27 Probable
Nx
None SE: 84.0 %
SOLmin: 11.5
REML: 0.5 min
AHI: 3.7 events/h
MSL: 2.5 min
MREML: 3.6
No. naps with
REM: 4
Negative DQB1*0602 Present True Nx
26 31 Probable
Nx
None SE: 84.6 %
SOLmin: 12.5
REML:
192.5 min
AHI: 6.2 events/h
MSL: 7.0 min
MREML: 0
No. naps with
REM: 0
Positive DQB1*0602 Absent Sleep
deprivation
27 32 Nx Mazindol SE: 84.8 %
SOLmin: 7.0
REML: 55.5 min
AHI: 14.4
events/h
MSL: 2.4 min
MREML: 1.3
No. naps with
REM: 4
Positive Blood could
not be
obtained or
patient
refused
Present True Nx
28 42 Probable
Nx
Omeprazole SE: 94.2 %
SOLmin: 4.5
REML:
59.0 min AHI:
26.1 events/h
MSL: 5.1 min
MREML:
5.5 No.
naps with
REM: 1
Positive Negative Absent OSAHS
29 30 Nx Amitriptyline, modafinil SE: 86.3 %
SOLmin: 34.5
REML: 54.0 min
AHI: 6.9 events/h
MSL: 7.9 min
MREML: 0
No. naps with
REM: 0
Urine could
not be
obtained
or patient
refused
Negative Absent Irregular
sleep
30 22 Nx None SE: 94.3 %
SOLmin: 10.5
REML: 64.0 min
AHI: 5.0 events/h
MSL: 7.5 min
MREML: 0
No. naps with
REM: 0
Negative Negative Absent Sleep
deprivation
31 36 Probable
Nx
None SE: 62.3 %
SOLmin: 22.0
REML: 46.0 min
AHI: 10.0
events/h
MSL: 9.0 min
MREML: 0
No. naps with
REM: 0
Urine could
not be
obtained
or patient
refused
Blood could
not be
obtained or
patient
refused
Present Poor sleep
hygiene
32 60 Nx Lansoprazole, co-codamol,
domperidone, modafinil
SE: 64.8 %
SOLmin: 17.5
REML: 58.0 min
AHI: 24.2
events/h
MSL:
10.4 min
MREML: 0
No. naps with
REM: 0
Positive Negative Absent OSAHS
33 20 Nx None SE: 89.6 %
SOLmin: 15.0
REML:
147.0 min
AHI: 7.3 events/h
MSL: 5.3 min
MREML: 1.0
No. naps with
REM: 3
Negative Negative Absent True Nx
34 48 Probable
Nx
None SE: 56.9 %
SOLmin: 7.0
REML: 66.0 min
AHI: 4.5 events/h
MSL: 4.5 min
MREML: 3.0
No. naps with
REM: 2
Negative Blood could
not be
obtained or
patient
refused
Present True Nx
35 36 Nx None SE: 57.4 %
SOLmin: 3.0
REML: 93.5 min
AHI: 38.5
events/h
MSL:
11.1 min
MREML: 0
No. naps with
REM: 0
Negative Blood could
not be
obtained or
patient
refused
Absent OSAHS
36 43 Nx Salbutamol, beclometasone,
iron tablets
SE: 68.9 %
SOLmin: 7.5
MSL: 1.8 min
MREML: 2.5
Negative DQB1*0602 Present True Nx
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Table 1 (continued)
Case Age Prior
diagnosis
Medication PSG results MSLT results Drug
screena
HLA type Features
of
cataplexy
Final
diagnosis
REML:
101.0 min
AHI: 108.7
events/h
No. naps with
REM: 1
37 57 Probable
Nx
None SE: 70.5 %
SOLmin: 0.0
REML: 0 min
AHI: 18.5
events/h
MSL: 0.8 min
MREML: 0.1
No. naps with
REM: 4
Negative DQB1*0602 Present True Nx
38 34 Nx Diclofenac SE: 77.4 %
SOLmin: 11.5
REML:
114.0 min
AHI: 2.0 events/h
MSL: 6.9 min
MREML:
10.0
No. naps with
REM: 1
Negative DRB1*15,
DRB5*01/
02,
DQB1*06,
DQA
Absent Poor sleep
hygiene
39 49 Nx Olanzapine, aspirin, metformin,
atorvastatin, furosemide,
diclofenac, co-codamol,
levothyroxine,
hydrocortisone,
SE: 78.8 %
SOLmin: 40.5
REML:
107.0 min
AHI: 16.5
events/h
MSL:
15.5 min
MREML: 0
No. naps with
REM: 0
Negative Negative Absent OSAHS
40 62 Nx Fentanyl patch, levothyroxine,
bendroflumethia-zide, aspirin,
amitriptyline, acetaminophen,
diazepam, perindopril
SE: 29.8 %
SOLmin: 62.0
REML: 0 min
AHI: 7.2 events/h
MSL:
20.0 min
MREML: 0
No. naps with
REM: 0
Negative Negative Absent OSAHS
41 63 Nx Amitryptiline, gliclazide,
metformin, simvastatin
SE: 37.9 %
SOLmin: 6.5
REML: 97.0 min
AHI: 71.1
events/h
MSL: 8.4 min
MREML:
0.8 No.
naps with
REM: 2
Negative Negative Present True Nx
Abbreviations:PSG polysomnography,MSLTmultiple sleep latency test,HLA human leukocyte antigen,Nx narcolepsy, SE sleep efficiency,REML rapid
eye movement latency, AHI apnea hypogea index,MSLmean sleep latency, REM rapid eye movement,OSAHS obstructive sleep apnea hypoventilation
syndrome, SOL sleep onset latency, MREML mean rapid eye movement latency
aWe routinely screen for drugs of abuse consisting of opiates, amphetamines, cocaine, methadone and benzodiazepines. Cannabinoids are also included
Smulant SSRI/SNRI TCA Benzodiazepine
Non-Narcolepcs 16 9 0 3
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Fig. 1 Drug treatment at referral
for 41 patients referred with a
‘diagnosis of narcolepsy’. SSRI
selective serotonin re-uptake
inhibitor, SNRI serotonin–
norepinephrine re-uptake
inhibitor, TCA tricyclic
antidepressant
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Prior to referral, 31 patients were prescribed CNS-altering
medication (Fig. 1). Of 28 patients receiving stimulants, 16
did not have narcolepsy. The specific drugs used in this latter
patient group were modafinil (n = 10), dexamphetamine
(n = 5) and methylphenidate (n = 1).
Discussion
A diagnosis of narcolepsy was incorrectly attributed to almost
50 % of patients referred for further opinion by a variety of
specialists and generalists. We are one of the only specialized
sleep clinics in the country; therefore, the high number of
innacurately diagnosed patients could result from referral bias.
Easily recognized and accurately diagnosed cases of narcolep-
sy which do not require clarification would possibly not be
referred to the sleep clinic for validation and we may be re-
ceiving only cases that pose difficult diagnostic conundrums
for referring doctors. The only significant difference between
narcoleptics and non-narcoleptics on presentation was a his-
tory of cataplexy, but this was not exclusive to narcoleptics.
[6] Objective testing using PSG andMSLTwas discriminatory
between groups, in keeping with previous studies. [7].
Accurate diagnosis of narcolepsy is critical for many rea-
sons, such as the impact it has on quality of life, driving,
employment, insurance and implications regarding pregnancy
in women. Treatment involves the use of controlled (e.g. am-
phetamines) and expensive (e.g. sodium oxybate) drugs which
should not be prescribed in error, as there are not inconsider-
able potential side effects (e.g. nausea, weight loss, psychiatric
complications), tolerance and possible addiction issues. [1]
Health service costs resulting from inappropriate treatment
are also an important consideration. [1, 3, 6] Furthermore,
several countries require a diagnosis of a medical condition
in order to approve prescription medication. With the use of
the Internet and increasing information disseminated on tele-
vision programmes, many people self-diagnose, presenting at
clinics with highly educated information and an excellent his-
tory of the disorder. This can be problematic because drug-
seeking individuals may present with fabricated narcolepsy
symptoms in order to obtain stimulant medications. [14] The
use of illegal substances can also influence the results of MSLT
and urine drug screening remains of great importance in accu-
rate diagnosis and treatment of adults and children. [2, 16].
The study sample of 41 patients over a 6-year time peri-
od—with 19 patients correctly diagnosed with narcolepsy—
might be considered small. However, the figures are high
when taken in the context of narcolepsy being an uncommon
disorder with a prevalence of 0.01 % in the general popula-
tion. A limitation to our study is that we were unable to cal-
culate the degree of certainty of diagnosis and if the source of
initial diagnosis had an impact on the confirmation rate due to
the small sample size. In an age when access to specialized
diagnostic facilities is unrestricted, it is of concern that such
diagnostic inaccuracy continues to occur. It is hoped that the
recent publication of the ICSD-3 with its detailed instructions
on diagnosing narcolepsy will further reduce misdiagnosis by
giving a clearer and more accurate description for providers to
use.
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